If the cells you would like to access are currently listed as unavailable
or you are ordering from outside of Europe please get in touch via
Contact@EBiSC.org.
DRICUi028-A
NE37A10025A
iPSC line
A CLIP contains information about a cell line including any
specific third party obligations relating to, for example,
licensing obligations or the donor consent which affect the
use of the cell line.
The EBiSC Access and Use Agreement must be completed along with an individual
Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org
for countersignature. The EAUA must be fully signed before proceeding with your order.
To receive the Certificate of Analysis, please contact us.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
Cell Line |
|
| hPSCreg name | DRICUi028-A |
| Alternative name(s) |
NE37A10025A
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Notes | Further anonymized information about the donor including demographic and clinical data will be made available on the Dementia Platforms UK data portal: https://portal.dementiasplatform.uk/ |
Provider |
|
| Depositor | UK Dementia Research Institute, Cardiff University (DRICU) |
| Owner | UK Dementia Research Institute, Cardiff University (DRICU) |
| Distributors |
EBiSC
|
| Derivation country | United Kingdom |
External Databases |
|
| hPSCreg | DRICUi028-A |
| BioSamples | SAMEA111486819 |
| Cellosaurus | CVCL_C6PG |
| Wikidata | Q117704304 |
General Information |
|
| This EBiSC line can be used for: |
Yes
Research use: allowed
Clinical use: no
Commercial use: no
|
Donor Information#
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 70-74 |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
Normal
Karyotyping method:
Molecular karyotyping by SNP array
http:// |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
|
External Databases (Donor) |
|
| BioSamples | SAMEA114036398 |
hIPSC Derivation#
General |
|
| Source cell type |
A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.
Synonyms
|
| Source cell origin |
A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.
Synonyms
|
| Age of donor (at collection) | 70-74 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
The following are the depositor culture conditions, they do not refer to any specific batch.
| Surface coating | Matrigel/Geltrex | |||||||||||||||||||||
| Feeder cells |
No |
|||||||||||||||||||||
| Passage method |
Enzyme-free cell dissociation
EDTA
|
|||||||||||||||||||||
| O2 Concentration | 18 % | |||||||||||||||||||||
| CO2 Concentration | 5 % | |||||||||||||||||||||
| Medium |
Other medium:
Base medium: Advanced DMEM/F12 (Gibco Thermo Fisher 12634010)
Main protein source: Albumine Serum concentration: 0 % Supplements
|
|||||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
|||||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
|||||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| TRA 1-60 |
Yes |
|||||
| NANOG |
Yes |
Morphology pictures
Differentiation Potency
In vitro directed differentiation
| Marker | Expressed |
| C-X-C Chemokine Receptor Type 4 |
Yes |
| SRY-box transcription factor 17 |
Yes |
Morphology
In vitro directed differentiation
| Marker | Expressed |
| C-X-C Chemokine Receptor Type 4 |
Yes |
| BRACHYURY |
Yes |
Morphology
In vitro directed differentiation
| Marker | Expressed |
| Paired box 6 |
Yes |
| orthodenticle homeobox 2 |
Yes |
Morphology
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
14q11.2 deletion of 730 kilobases (chr14:22239075-22969453). No other abnormalities >0.4 Mb.
Passage number: 13
Karyotyping method:
Molecular karyotyping by SNP array
http:// |
Other Genotyping (Cell Line) |
|